Shmuel Hess - 26 Aug 2026 Form 4 Insider Report for MediWound Ltd. (MDWD)

Reporting relationship: COO & Chief Commercial Officer
Issuer ticker: MDWD
Reported as of: 26 Aug 2026
Net transaction value: -$75,394
SEC form: 4
Accepted by SEC: 28 Aug 2026, 16:02:21 UTC
Prior SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Yaron Meyer, attorney-in-fact

Key filing fact

Shmuel Hess filed Form 4 for MediWound Ltd. (MDWD) on 28 Aug 2026.

Key facts

This page summarizes Shmuel Hess's Form 4 filing for MediWound Ltd. (MDWD).
5 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 28 Aug 2026, 16:02.

Change

Previous filing in this sequence was filed on 18 Mar 2026.
Current net transaction value: -$75,394.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002085305 Primary reporting owner

Hess Shmuel

Relationship: COO & Chief Commercial Officer
Address: C/O MEDIWOUND LTD., 42 HAYARKON STREET, YAVNE, ISRAEL
Signature: /s/ Yaron Meyer, attorney-in-fact
Signature date: 28 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDWD transaction

Ordinary Shares

Sale

Transaction value: $24,245
Shares: -1,865
Change %: -100%
Price: $13.00
Shares after: 0
Date: 26 Aug 2026
Ownership: Direct
Footnotes: F8

MDWD transaction

Ordinary Shares

Sale

Transaction value: $25,173
Shares: -1,979
Change %: -100%
Price: $12.72
Shares after: 0
Date: 27 Aug 2026
Ownership: Direct
Footnotes: F9

MDWD transaction

Ordinary Shares

Sale

Transaction value: $25,976
Shares: -1,979
Change %: -100%
Price: $13.13
Shares after: 0
Date: 27 Aug 2026
Ownership: Direct
Footnotes: F9

MDWD holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 4,085
Date: 26 Aug 2026
Ownership: Direct
Footnotes: F1, F10

MDWD holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,000
Date: 26 Aug 2026
Ownership: Direct
Footnotes: F2, F10

MDWD holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,000
Date: 26 Aug 2026
Ownership: Direct
Footnotes: F3, F10

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MDWD transaction Derivative

Stock Option (right to buy ordinary shares)

Options Exercise

Transaction value
Shares: -5,000
Change %: -16%
Price: $0.000000^*
Shares after: 27,000
Date: 26 Aug 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 5,000
Exercise price: $8.13
Footnotes: F4, F8

MDWD transaction Derivative

Stock Option (right to buy ordinary shares)

Options Exercise

Transaction value
Shares: -11,000
Change %: -41%
Price: $0.000000^*
Shares after: 16,000
Date: 27 Aug 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 11,000
Exercise price: $8.13
Footnotes: F4, F9

MDWD holding Derivative

Stock Option (right to buy ordinary shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 32,681
Date: 26 Aug 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 32,681
Exercise price: $12.73
Footnotes: F5, F10

MDWD holding Derivative

Stock Option (right to buy ordinary shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 24,000
Date: 26 Aug 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 24,000
Exercise price: $18.54
Footnotes: F6, F10

MDWD holding Derivative

Stock Option (right to buy ordinary shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 31,000
Date: 26 Aug 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 31,000
Exercise price: $17.60
Footnotes: F7, F10

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 10 footnotes

Footnote F1

The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F2

The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F3

The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F4

The options reported in this row are the remaining outstanding options from a grant of 39,000 options that were granted to the Reporting Person on December 1, 2023 and that have been vesting in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F5

The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F6

The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F7

The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F8

The Reporting Person exercised 5,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 1,865 ordinary shares to the Reporting Person. All 1,865 ordinary shares received upon the net exercise were sold on the same day as reported in Table I.

Footnote F9

The Reporting Person exercised 11,000 stock options on a net (cashless) basis. Shares otherwise issuable upon exercise were withheld to satisfy the aggregate exercise price, resulting in the net issuance of 3,958 ordinary shares to the Reporting Person. All 3,958 ordinary shares received upon the net exercise were sold on the same day as reported in Table I.

Footnote F10

There were no transactions effected in respect of the securities reported in the rows marked with this footnote, and the holdings in such rows are being included for informational purposes only.